Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Modelling the impact of a Schistosoma mansoni vaccine and mass drug administration to achieve morbidity control and transmission elimination
Klodeta Kura, James E. Truscott, Jaspreet Toor, et al.
PLoS neglected tropical diseases (2019) Vol. 13, Iss. 6, pp. e0007349-e0007349
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Schistosomiasis—from immunopathology to vaccines
Donald P. McManus, Robert Bergquist, Pengfei Cai, et al.
Seminars in Immunopathology (2020) Vol. 42, Iss. 3, pp. 355-371
Open Access | Times Cited: 147
Schistosomiasis vaccine development: update on human clinical trials
Adebayo J. Molehin
Journal of Biomedical Science (2020) Vol. 27, Iss. 1
Open Access | Times Cited: 122
Disruptions to schistosomiasis programmes due to COVID-19: an analysis of potential impact and mitigation strategies
Klodeta Kura, Diepreye Ayabina, Jaspreet Toor, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene (2021) Vol. 115, Iss. 3, pp. 236-244
Open Access | Times Cited: 36
Soil-transmitted helminths: A critical review of the impact of co-infections and implications for control and elimination
Sarah Lebu, Winnie Kibone, Chimdi Muoghalu, et al.
PLoS neglected tropical diseases (2023) Vol. 17, Iss. 8, pp. e0011496-e0011496
Open Access | Times Cited: 16
Achieving Elimination as a Public Health Problem for Schistosoma mansoni and S. haematobium: When Is Community-Wide Treatment Required?
Jaspreet Toor, David Rollinson, Hugo C. Turner, et al.
The Journal of Infectious Diseases (2019) Vol. 221, Iss. Supplement_5, pp. S525-S530
Open Access | Times Cited: 37
Schistosoma haematobium Extracellular Vesicle Proteins Confer Protection in a Heterologous Model of Schistosomiasis
Gebeyaw Getnet Mekonnen, Bemnet Tedla, Darren Pickering, et al.
Vaccines (2020) Vol. 8, Iss. 3, pp. 416-416
Open Access | Times Cited: 34
Determining the optimal strategies to achieve elimination of transmission for Schistosoma mansoni
Klodeta Kura, Diepreye Ayabina, T. Déirdre Hollingsworth, et al.
Parasites & Vectors (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 19
Human Schistosomiasis Vaccines as Next Generation Control Tools
Peter J. Hotez, María Elena Bottazzi
Tropical Medicine and Infectious Disease (2023) Vol. 8, Iss. 3, pp. 170-170
Open Access | Times Cited: 11
Evaluating the Immunoprotective and Diagnostic Potential of Schistosoma mansoni Epitopes from Sm050890 and Sm141290 Proteins Identified Through Reverse Vaccinology
Flávio Martins de Oliveira, Gabriela Francine Martins Lopes, Rosy Iara Maciel de Azambuja Ribeiro, et al.
Acta Parasitologica (2025) Vol. 70, Iss. 1
Closed Access
A functional enzymatic assay as potential readout for a clinical trial of a schistosomiasis vaccine
Desalegn W. Kifle, Mumtaz Yaseen Balkhi, Yasuko Ono, et al.
npj Vaccines (2025) Vol. 10, Iss. 1
Open Access
The Sm14+GLA-SE Recombinant Vaccine Against Schistosoma mansoni and S. haematobium in Adults and School Children: Phase II Clinical Trials in West Africa
Amadou Tidjani Ly, Doudou Diop, Modou Diop, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 316-316
Open Access
Evaluating the potential impact of interruptions to neglected tropical disease programmes due to COVID-19
T. Déirdre Hollingsworth, Pauline Mwinzi, Andreia Vasconcelos, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene (2021) Vol. 115, Iss. 3, pp. 201-204
Open Access | Times Cited: 24
Safety and infectivity of female cercariae in Schistosoma-naïve, healthy participants: a controlled human Schistosoma mansoni infection study
Jan Pieter R. Koopman, Emma L. Houlder, Jacqueline J. Janse, et al.
EBioMedicine (2023) Vol. 97, pp. 104832-104832
Open Access | Times Cited: 10
The impact of mass drug administration on Schistosoma haematobium infection: what is required to achieve morbidity control and elimination?
Klodeta Kura, Robert J. Hardwick, James E. Truscott, et al.
Parasites & Vectors (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 26
SCHISTOX: An individual based model for the epidemiology and control of schistosomiasis
Matthew Graham, Diepreye Ayabina, Tim Lucas, et al.
Infectious Disease Modelling (2021) Vol. 6, pp. 438-447
Open Access | Times Cited: 23
Antiparasitic Properties of Propolis Extracts and Their Compounds
Lucas Antônio de Lima Paula, Ana Carolina Bolela Bovo Cândido, Mário F. C. Santos, et al.
Chemistry & Biodiversity (2021) Vol. 18, Iss. 9
Open Access | Times Cited: 23
Fifteen Years of Sm-p80-Based Vaccine Trials in Nonhuman Primates: Antibodies From Vaccinated Baboons Confer Protection in vivo and in vitro From Schistosoma mansoni and Identification of Putative Correlative Markers of Protection
Weidong Zhang, Loc Le, Gul Ahmad, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 23
Revisiting density-dependent fecundity in schistosomes using sibship reconstruction
M. Inês Neves, Charlotte Gower, Joanne P. Webster, et al.
PLoS neglected tropical diseases (2021) Vol. 15, Iss. 5, pp. e0009396-e0009396
Open Access | Times Cited: 16
Transmission-Blocking Vaccines against Schistosomiasis Japonica
Chika P. Zumuk, Malcolm K. Jones, Séverine Navarro, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1707-1707
Open Access | Times Cited: 2
Age-group associations of schistosomiasis prevalence from trial data, Côte d’Ivoire, Kenya and the United Republic of Tanzania
Ryan E. Wiegand, Maurice R. Odiere, Safari Kinung’hi, et al.
Bulletin of the World Health Organization (2024) Vol. 102, Iss. 04, pp. 265-275
Open Access | Times Cited: 2
Vaccine value profile for schistosomiasis
Gavin Yamey, Kaci Kennedy McDade, Roy M. Anderson, et al.
Vaccine (2024), pp. 126020-126020
Open Access | Times Cited: 2
Policy implications of the potential use of a novel vaccine to prevent infection with Schistosoma mansoni with or without mass drug administration
Klodeta Kura, Benjamin Collyer, Jaspreet Toor, et al.
Vaccine (2020) Vol. 38, Iss. 28, pp. 4379-4386
Open Access | Times Cited: 17
What is the impact of acquired immunity on the transmission of schistosomiasis and the efficacy of current and planned mass drug administration programmes?
Klodeta Kura, Robert J. Hardwick, James E. Truscott, et al.
PLoS neglected tropical diseases (2021) Vol. 15, Iss. 12, pp. e0009946-e0009946
Open Access | Times Cited: 13
Transmission Modelling for Human Schistosomiasis Incorporating Vaccination: Guiding Decision- and Policymaking
Ursula Panzner
(2024)
Open Access | Times Cited: 1
Controlled human infection models to evaluate schistosomiasis and hookworm vaccines: where are we now?
Jan Pieter R. Koopman, Emmanuella Driciru, Meta Roestenberg
Expert Review of Vaccines (2021) Vol. 20, Iss. 11, pp. 1369-1371
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top